Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018;44(4):431-440.
doi: 10.1080/00952990.2017.1420795. Epub 2018 Jan 15.

Pharmacogenetic analysis of opioid dependence treatment dose and dropout rate

Richard C Crist  1 , James Li  2 , Glenn A Doyle  1 , Alex Gilbert  2 , Bryan M Dechairo  2 , Wade H Berrettini  1
Affiliations

Pharmacogenetic analysis of opioid dependence treatment dose and dropout rate

Richard C Crist et al. Am J Drug Alcohol Abuse. 2018.

Abstract

Background: Currently, no pharmacogenetic tests for selecting an opioid-dependence pharmacotherapy have been approved by the US Food and Drug Administration.

Objectives: Determine the effects of variants in 11 genes on dropout rate and dose in patients receiving methadone or buprenorphine/naloxone (ClinicalTrials.gov Identifier: NCT00315341).

Methods: Variants in six pharmacokinetic genes (CYP1A2, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4) and five pharmacodynamic genes (HTR2A, OPRM1, ADRA2A, COMT, SLC6A4) were genotyped in samples from a 24-week, randomized, open-label trial of methadone and buprenorphine/naloxone for the treatment of opioid dependence (n = 764; 68.7% male). Genotypes were then used to determine the metabolism phenotype for each pharmacokinetic gene. Phenotypes or genotypes for each gene were analyzed for association with dropout rate and mean dose.

Results: Genotype for 5-HTTLPR in the SLC6A4 gene was nominally associated with dropout rate when the methadone and buprenorphine/naloxone groups were combined. When the most significant variants associated with dropout rate were analyzed using pairwise analyses, SLC6A4 (5-HTTLPR) and COMT (Val158Met; rs4860) had nominally significant associations with dropout rate in methadone patients. None of the genes analyzed in the study was associated with mean dose of methadone or buprenorphine/naloxone.

Conclusions: This study suggests that functional polymorphisms related to synaptic dopamine or serotonin levels may predict dropout rates during methadone treatment. Patients with the S/S genotype at 5-HTTLPR in SLC6A4 or the Val/Val genotype at Val158Met in COMT may require additional treatment to improve their chances of completing addiction treatment. Replication in other methadone patient populations will be necessary to ensure the validity of these findings.

Keywords: COMT; Opioid dependence; SERT; buprenorphine; methadone; pharmacogenetics.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest:

Genotyping on Assurex Health GeneSight® Analgesic, Psychotropic and ADHD panels was performed by Assurex Health Inc. as an in-kind donation. J.L., A.G., and B.M.D. are employees and shareholders of Assurex Health Inc. The authors declare no other conflicts of interest.

Figures

Figure 1
Figure 1
Cumulative dropout rate for opioid dependent patients treated with methadone by genotype at either COMT (rs4680) or SLC6A4 (5-HTTLPR). Cumulative dropout for each week of the trial was defined as the percentage of patients who did not submit a urine sample on that week or at any subsequent week. Chi-square analyses were used to compare dropout at week 24 of the study by rs4680 or 5-HTTLPR genotype. A) Patients with the Val/Val genotype in COMT dropped out at a significantly higher rate by week 24 (16.7%) than patients with the Met/Met genotype (6.3%, p = 0.037). B) Significantly more patients with the S/S genotype in SLC6A4 dropped out of by week 24 treatment (21.2%) compared to patients with the L/S genotype (9.9%, p = 0.029).
See this image and copyright information in PMC

References

    1. Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;2:CD002207. - PMC - PubMed
    1. Crist RC, Clarke TK, Ang A, Ambrose-Lanci LM, Lohoff FW, Saxon AJ, et al. An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans. Neuropsychopharmacology. 2013 Sep;38(10):2003–10. - PMC - PubMed
    1. Brewer DD, Catalano RF, Haggerty K, Gainey RR, Fleming CB. A meta-analysis of predictors of continued drug use during and after treatment for opiate addiction. Addiction. 1998 Jan;93(1):73–92. - PubMed
    1. Clarke TK, Crist RC, Ang A, Ambrose-Lanci LM, Lohoff FW, Saxon AJ, et al. Genetic variation in OPRD1 and the response to treatment for opioid dependence with buprenorphine in European-American females. Pharmacogenomics J. 2014 Jun;14(3):303–8. - PMC - PubMed
    1. Senbanjo R, Wolff K, Marshall EJ, Strang J. Persistence of heroin use despite methadone treatment: poor coping self-efficacy predicts continued heroin use. Drug Alcohol Rev. 2009 Nov;28(6):608–15. - PubMed

Publication types

Substances

Associated data